Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Just a bunch of kids

<< Previous

Bullboard Posts

Next >>

Comment by InvestorSaraon Nov 24, 2020 2:02pm

259 Views

Post# 31962126

RE:Just a bunch of kids

As much as we don't like the New Kids on the Block throwing away money we must remember we all started somewhere too. Flipping profits of $100, then $1000, $10k $100k.... Let them have their fun. A company like this will either make or break them this early in the game ;)

<< Previous

Bullboard Posts

Next >>

Michael Gentile tops up stake in Astra Exploration